What is known and objective In China, with the increased number of oncology patients and use of novel antitumour drugs, the demand of oncology clinical pharmacy services is also growing. However, the current status of oncology clinical pharmacy services in China was seldom reported. The purpose of the study was to investigate the contents and features of oncology clinical pharmacy services and self‐evaluations of the oncology pharmacists in China, and to identify related problems for further development. Methods A 55‐item online questionnaire was distributed to oncology‐related clinical pharmacists in Chinese hospitals in January 2019. Pharmacists answered the questions on the WeChat platform. Data were analysed using descriptive statistics. Results and discussion The respondents of the 166 valid questionnaires were from 29 provinces (or autonomous regions or municipalities). Their average working experience for clinical pharmacy was 4.86 years. The average duration of their clinical services was 3.27 h/d. The clinical pharmacy services consist of 15 types, and their workload on each service type was summarized. Pharmacists are not frequently participating in establishing pharmacotherapy protocols, therapeutic drug monitoring and pharmacogenetic/pharmacogenomic services. About 80% (81.33%) of the pharmacists thought that other healthcare professionals knew the nature of their work. The biggest barrier for career development of the pharmacists was insufficiency of professional skills. In most cases, the clinical service accounted for <30% of the overall performance evaluation of the pharmacists. Most of the participating pharmacists were not satisfied with their current salary. The overall evaluation score for their career happiness was 6.27 out of 10. What is new and conclusion The value of oncology clinical pharmacists is being increasingly recognized, but advanced services need further expansion. Increasing the time serving in patient care, optimizing performance evaluation mechanisms and strengthening their skills are possible ways for pharmacists to provide superior services. This study showed the current service of oncology clinical pharmacists in most parts of China, which may provide reference for policymakers, promote international communications and shed light on future development of oncology clinical pharmacy.
In recent years, with an increasing number of oncology patients and continuous introduction of new antitumor drugs in China, the demand for oncology clinical pharmacy services is growing rapidly, which is both an opportunity and a challenge for clinical pharmacists. However, there have not been many reports about different types of oncology clinical pharmacy services in China. In this report, we have summarized different oncology clinical pharmacy services commonly practiced in Chinese hospitals based on our review of the literature and current practice in our hospital. We are reporting the training programs and the certification process for oncology clinical pharmacists, basic and advanced patient services, pharmacist‐driven and pharmacist‐participated guidelines/expert consensuses/books on oncology pharmacotherapy, as well as professional and public health education performed by pharmacists. Based on what we have observed, oncology clinical pharmacy services in China are relatively comprehensive, however, there are needs for expanding certain advanced pharmacy services. Increasing the time spent on clinical services, improving pharmacists' competency, and optimizing clinical pharmacy workflow and evaluation mechanisms are important for enhancing the value of oncology clinical pharmacists in China.
Background: With the growing number of oncology patients and novel anti-tumor medications, the demand of oncology clinical pharmacy services is increasing rapidly in China. However, the current status of oncology clinical pharmacy services in China were seldom reported. The purpose of the study was to investigate the contents and features of oncology clinical pharmacy services and self-evaluations of the oncology pharmacists in China, and to identify related problems for its further development. Methods: A 55-item online questionnaire was distributed to oncology-related clinical pharmacists in Chinese hospitals in January 2019. Pharmacists answered the questions on the WeChat platform. Data were analyzed using descriptive statistics. Results: The respondents of the 166 valid questionnaires were from 29 provinces (or autonomous regions or municipalities). Their average working experience for clinical pharmacy was 4.86 years. The average duration of their clinical services was 3.27 hours/day. The clinical pharmacy services consist of 15 types and their workload on each service type were identified. Pharmacists thought they were not good at establishing pharmacotherapy protocols, participating in therapeutic drug monitoring, pharmacy consultation and pharmacogenetic/pharmacogenomic service. About 80% (81.33%) of the pharmacists thought other healthcare professionals knew the nature of their work, and some services were very welcomed by clinical departments. The biggest barrier for career development of the pharmacists was insufficiency of professional skills. In most cases, the clinical service accounted for less than 30% of the overall performance evaluation of the pharmacists. Most of the participating pharmacists were not satisfied with their current salary. The overall evaluation score for their career wellbeing was 6.27 out of 10. Conclusions: The value of oncology clinical pharmacists is being increasingly recognized, but advanced services need further expansion. Increasing the time serving in clinical units, optimizing performance evaluation and strengthening their skills are possible ways for pharmacists to provide superior services. This study showed the current service of oncology clinical pharmacists in most parts of China, which may provide reference for policy makers, promote international communications and shed light on future development of oncology clinical pharmacy in China. Key words: Oncology, pharmacist, clinical pharmacy services, self-evaluation, survey, China
What Is Known and Objective: To investigate and describe the real-world use of IBI305, a biosimilar of bevacizumab, across all approved indications in the first 12 months since its entry in National cancer center of China.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.